Redmile Group, LLC Fate Therapeutics Inc Transaction History
Redmile Group, LLC
- $822 Million
- Q2 2025
A detailed history of Redmile Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 12,872,946 shares of FATE stock, worth $12.4 Million. This represents 1.75% of its overall portfolio holdings.
Number of Shares
12,872,946
Previous 12,872,946
-0.0%
Holding current value
$12.4 Million
Previous $10.2 Million
41.77%
% of portfolio
1.75%
Previous 1.07%
Shares
13 transactions
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Black Rock Inc. New York, NY10.1MShares$9.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.42 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$4.36 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$3.26 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.24 Million1.27% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $93.1M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...